Latest Sironax News & Updates

See the latest news and media coverage for Sironax. We track all announcements, press releases, and industry mentions in real time, all in one place.

Sironax

Biopharmaceutical company developing treatments for neurodegenerative, inflammatory, and metabolic diseases

sironax.com

Headquarters: Waltham, United States
Founded year: 2017
Company type: Private company
Number of employees: 71–200
Industry: Pharmaceuticals

Last updated October 29

Latest news about Sironax

In short: Sironax received $125 million from Novartis for its brain-delivery platform and reached 50% enrollment in obesity trial

Company announcements

October 29 Sironax

Sironax presents three SIR2501 abstracts at Neuroscience 2026

The SARM1 inhibitor SIR2501 shows safety and activity in ALS and CIPN trials. Selections include preclinical neuroprotection data.

October 13 Sironax

Sironax Advances Enrollment in Phase 2 FORGE-LM Obesity Trial of NAMPT Activator SIR4156

The company reached 50% enrollment for the Phase 2 trial evaluating SIR4156 with semaglutide in obesity. The study assesses body fat mass and safety outcomes.

October 7 Sironax

Sironax welcomes Dr. Chris Fang to its team

The new leader joins Sironax's global team, reinforcing the company's drug discovery and development capabilities.

September 16 Sironax

Novartis exercises option to acquire Sironax's brain delivery platform

Sironax receives $125 million and retains rights to selected assets while advancing its clinical pipeline with the proceeds.

Media coverage

October 27 Longevity Technology

Can an NAD+ booster protect muscle on semaglutide?

Sironax is about halfway to its enrollment target in a Phase 2 trial of an oral NAMPT activator for adults with obesity.

October 12 The Manila Times

Sironax Advances Enrollment in Phase 2 FORGE-LM Obesity Trial of NAMPT Activator SIR4156

Evaluating first-in-class asset to potentially address current obesity treatment deficiencies by promoting weight loss and preserving lean body mass WALTHAM, Mass., Oct. 13, 2026 (GLOBE...

September 15 MedCity News

Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M

Novartis is acquiring a Sironax platform technology designed to transport a range of drug modalities across the protective blood-brain barrier. The deal comes as Novartis...

May 11 Markets Insider

Sironax's SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)

CIPN is a common nerve-damaging side effect of chemotherapy with no FDA-approved treatment optionsFast Track designation reflects the significant...

Never miss news about Sironax

Track Sironax and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Sironax competitors & trending companies

Browse news for competitors to Sironax and other trending companies.